Abstract
Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are characterized by rapid-onset respiratory failure following a variety of direct and indirect insults to the parenchyma or vasculature of the lungs. Mortality from ALI/ARDS is substantial, and current therapy primarily emphasizes mechanical ventilation and judicial fluid management plus standard treatment of the initiating insult and any known underlying disease. Current pharmacotherapy for ALI/ARDS is not optimal, and there is a significant need for more effective medicinal chemical agents for use in these severe and lethal lung injury syndromes. To facilitate future chemical-based drug discovery research on new agent development, this paper reviews present pharmacotherapy for ALI/ARDS in the context of biological and biochemical drug activities. The complex lung injury pathophysiology of ALI/ARDS offers an array of possible targets for drug therapy, including inflammation, cell and tissue injury, vascular dysfunction, surfactant dysfunction, and oxidant injury. Added targets for pharmacotherapy outside the lungs may also be present, since multiorgan or systemic pathology is common in ALI/ARDS. The biological and physiological complexity of ALI/ARDS requires the consideration of combined-agent treatments in addition to singleagent therapies. A number of pharmacologic agents have been studied individually in ALI/ARDS, with limited or minimal success in improving survival. However, many of these agents have complementary biological/biochemical activities with the potential for synergy or additivity in combination therapy as discussed in this article.
Keywords: ARDS, ALI, inflammatory lung injury, lung injury therapy, anti-inflammatory therapy, surfactant therapy, INO therapy, antioxidants, pharmacotherapy
Current Medicinal Chemistry
Title: Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome
Volume: 15 Issue: 19
Author(s): Krishnan Raghavendran, Gloria S. Pryhuber, Patricia R. Chess, Bruce A. Davidson, Paul R. Knight and Robert H. Notter
Affiliation:
Keywords: ARDS, ALI, inflammatory lung injury, lung injury therapy, anti-inflammatory therapy, surfactant therapy, INO therapy, antioxidants, pharmacotherapy
Abstract: Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are characterized by rapid-onset respiratory failure following a variety of direct and indirect insults to the parenchyma or vasculature of the lungs. Mortality from ALI/ARDS is substantial, and current therapy primarily emphasizes mechanical ventilation and judicial fluid management plus standard treatment of the initiating insult and any known underlying disease. Current pharmacotherapy for ALI/ARDS is not optimal, and there is a significant need for more effective medicinal chemical agents for use in these severe and lethal lung injury syndromes. To facilitate future chemical-based drug discovery research on new agent development, this paper reviews present pharmacotherapy for ALI/ARDS in the context of biological and biochemical drug activities. The complex lung injury pathophysiology of ALI/ARDS offers an array of possible targets for drug therapy, including inflammation, cell and tissue injury, vascular dysfunction, surfactant dysfunction, and oxidant injury. Added targets for pharmacotherapy outside the lungs may also be present, since multiorgan or systemic pathology is common in ALI/ARDS. The biological and physiological complexity of ALI/ARDS requires the consideration of combined-agent treatments in addition to singleagent therapies. A number of pharmacologic agents have been studied individually in ALI/ARDS, with limited or minimal success in improving survival. However, many of these agents have complementary biological/biochemical activities with the potential for synergy or additivity in combination therapy as discussed in this article.
Export Options
About this article
Cite this article as:
Raghavendran Krishnan, Pryhuber S. Gloria, Chess R. Patricia, Davidson A. Bruce, Knight R. Paul and Notter H. Robert, Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome, Current Medicinal Chemistry 2008; 15 (19) . https://dx.doi.org/10.2174/092986708785132942
DOI https://dx.doi.org/10.2174/092986708785132942 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Py-GC/MS as a Powerful and Rapid Tool for Determining Lignin Compositional and Structural Changes in Biological Processes
Current Analytical Chemistry Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors
Current Medicinal Chemistry Neutrophil Proteome: Lessons from Different Standpoints
Protein & Peptide Letters Two Different Functions of Doxycycline Which is Both An Antimicrobial Agent and An Immune Modulator
Anti-Infective Agents in Medicinal Chemistry Bacterial RNA Polymerase Inhibitors: An Organized Overview of their Structure, Derivatives, Biological Activity and Current Clinical Development Status
Current Medicinal Chemistry Growth and Attachment of Embryonic Stem Cell Colonies on Single Nanofibers
Micro and Nanosystems Phospho-eIF4E: A New Target for Acute Myeloid Leukemia
Current Protein & Peptide Science Design, Synthesis and Biological Evaluation of Some Novel Thiazole-2- Carboxamide Derivatives as Antitumor Agents
Letters in Drug Design & Discovery Subject Index To Volume 8
Current Pharmaceutical Design Calcium-Regulating Hormonal System and HMGB1 in Cardiomyopathies
Endocrine, Metabolic & Immune Disorders - Drug Targets Applications of Protein Microarray Technology
Combinatorial Chemistry & High Throughput Screening Prodrug Design to Improve Pharmacokinetic and Drug Delivery Properties: Challenges to the Discovery Scientists
Current Medicinal Chemistry Regulatory Strategies for Cell Death in Neurological Diseases
CNS & Neurological Disorders - Drug Targets The HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (Part V ☆ ): Capravirine and Its Analogues
Current Medicinal Chemistry Procalcitonin as a Prognostic Factor in Patients with COVID-19 in Southwestern Iran
Infectious Disorders - Drug Targets Editorial (Thematic Issue: Medicinal Chemistry Applied to Natural Products in Neglected Drug Discovery)
Combinatorial Chemistry & High Throughput Screening Recent Studies on the Pharmacological Activities and Structural Modifications of Compound-K
Mini-Reviews in Medicinal Chemistry The Changing Face of Hepatitis C: Recent Advances on HCV Inhibitors Targeting NS5A
Current Medicinal Chemistry <i>Chemi-Informatic</i> Approach to Investigate Putative Pharmacoactive Agents of Plant Origin to Eradicate COVID-19
Coronaviruses